Nursing Pharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of VEGFR and other tyrosine kinases: cabozantinib (Cometriq)

Nursing Cancer ChemotherapyPharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of VEGFR and other tyrosine kinases: cabozantinib (Cometriq)

Cabozantinib (Cometriq) inhibits several tyrosine kinases including:
1. VEGFR
2. MET
3. RET
4. A & B
5. B & C
6. A, B & C
Cabozantinib (Cometriq) clinical use/uses:
1. Advanced renal cell carcinoma (RCC) in patients who had received previous antiangigogenic treatment.
2. Metastatic renal cancer in poor risk patients
3. In certain subgroups of patients with lung adenocarcinoma
4. For patients with medullary thyroid cancer
5. A & B
6. B & C
7. A & C
8. D only
9. A, B, C & D
Cabozantinib may be useful in treating metastatic medullary thyroid disease. advanced medullary thyroid cancer in cases when surgery with or without radiation treatment does not cure the patient, treatment with cabozantinib may give the patient the best opportunity for increased progression free survival.
1. True
2. Falls
Comparing cabozantinib and vandetanib:
1. Cabozantinib may provide a comparatively greater benefit.
2. Cabozantinib would be a drug of choice for patients with certain cardiac dysfunction since vandetanib may prolong the QT interval.
3. Both
4. Neither
Cabozantinib pharmacodynamic/pharmacokinetics:
1. Cabozantinib is metabolized by the liver utilizing primarily the CYP3A4 cytochrome P450 isoform (cytochrome P450 microsomal drug metabolizing system).
2. Elimination half-life is approximately 55 hours (Cometriq)
3. Both
4. Neither
Cabozantinib excretion:
1. Feces: about 54%
2. Urine: about 30%
3. Both
4. Neither
Cabozantinib may be used to treat advanced hepatocellular carcinoma (Cabometyx), in patients previously treated with sorafenib
1. True
2. False
Contraindications to the use of cabozantinib:
1. Patient with a recent history of bleeding.
2. Should be discontinued in patients exhibiting G.I. perforations and fistulas.
3. Both
4. Neither
Frequently noted adverse effects following cabozantinib administration include which one(s) of the following?
1. Diarrhea
2. Nausea
3. Hypertension
4. Pleural effusion
5. A & B
6. B & C
7. A, B, C & D
Since cabozantinib administration may result in abnormalities in pregnancy, females of reproductive potential should use effective contraception during treatment and continue effective contraception for four months following the last cabozantinib dosage.
1. True
2. Falls